Jade Biosciences, Inc. Debt Securities, Trading, Unrealized Loss
Jade Biosciences, Inc. (JBIO) reported Debt Securities, Trading, Unrealized Loss of $55.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DebtSecuritiesTradingUnrealizedLoss · last filed 2025-04-25
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for the quarter ending 2025-03-31 was $55.00K, a 79.63% decline year-over-year.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for the quarter ending 2024-06-30 was $50.00K, a 127.27% increase year-over-year.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for the quarter ending 2024-03-31 was $270.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for the quarter ending 2023-06-30 was $22.00K, a 84.40% decline year-over-year.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for fiscal 2024 was $132.00K.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for fiscal 2022 was $407.00K, a 589.83% increase from fiscal 2021.
- Jade Biosciences, Inc. debt securities, trading, unrealized loss for fiscal 2021 was $59.00K.
| Period end | Debt Securities, Trading, Unrealized Loss 3 month | Debt Securities, Trading, Unrealized Loss 6 month | Debt Securities, Trading, Unrealized Loss 12 month |
|---|---|---|---|
| 2025-03-31 | $55.00K 10-Q · filed 2025-04-25 | ||
| 2024-12-31 | $132.00K 10-K · filed 2025-03-27 | ||
| 2024-06-30 | $50.00K 10-Q · filed 2024-11-12 | $320.00K derived: sum of 2 quarters · filed 2025-04-25 | |
| 2024-03-31 | $270.00K 10-Q · filed 2025-04-25 | ||
| 2023-06-30 | $22.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $407.00K 10-K · filed 2024-03-25 | ||
| 2022-06-30 | $141.00K 10-Q · filed 2023-11-13 | $726.00K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $585.00K 10-Q · filed 2023-11-13 | ||
| 2021-12-31 | $59.00K 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |